Home > Insider Trading > Filing (0001181431-13-017178)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356576	Supernus Pharmaceuticals Inc	SUPN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219844	S Gregory Patrick	C/O Supernus Pharmaceuticals, Inc. 1550 East Gude Drive Rockville MD 20850	Vp, Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-03-14	5,000	$6.95	8,903	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Employee Stock Option (Right to Buy)	$7.90		2023-02-05	70,000	70,000	Direct
Common Stock	Employee Stock Option (Right to Buy)	$5.88		2021-12-30	105,000	105,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2023-02-05	70,000	70,000	Direct
2021-12-30	105,000	105,000	Direct

Footnotes

The reported purchase was made pursuant to a pre-arranged program for buying stock adopted on December 27, 2012, pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.85 to $6.99, inclusive. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
The option vests in four equal annual installments beginning on February 5, 2014.
25% of the shares subject to the option vested on 12/30/12, and the remaining shares subject to the option will vest in approximately equal quarterly installments over the following three years.